Study Finds: Alzheimer’s Affects 91% of  Biological Pathways in the Brain.

Scientists have uncovered the key molecular biology pathways that drive changes in cells and contribute to Alzheimer’s disease.

The team of scientists found that although almost all known signaling pathways have been implicated in the disease, the biological mechanisms most commonly associated with it – including those related to the immune system, metabolism and long-term depression – have nevertheless evolved over the 30 years major technological advances have not changed significantly. The scientists’ work was published in Frontiers in Aging Neuroscience.

A comprehensive review of this scientific literature shows that immunological, metabolic, and depression-related signaling pathways are the most frequently cited in disease mechanisms.

Study Finds: Alzheimer’s Affects 91% of  Biological Pathways in the Brain.

Alzheimer’s Disease Statistics in the United States.

Alzheimer’s disease affects nearly six million older adults in the United States, a number expected to double by 2050.

Alzheimer’s disease, a complicated neurological disorder that is already the sixth leading cause of death, is a complex neurodegenerative disorder that causes memory loss, confusion, poor judgment, depression, delusions and agitation that robs people of their ability to live independently.

Currently, there are few effective treatments and no known cure for Alzheimer’s disease because the biological mechanisms behind the disease are not well understood.

Not only is Alzheimer’s disease incredibly complex, but its pathology encompasses most of the known biological pathways. This means that the effects of the disease on the body are much broader than we thought. ’

“The burden of Alzheimer’s disease is steadily increasing, propelling us toward a neurological epidemic,” said Winston A. Hide, Ph.D., director of the Core Facility for Precision RNA Medicine at BIDMC and associate professor of medicine from Harvard Medical School.

Biological Pathways in Alzheimer’s Disease

The researchers found that 91% of the signaling pathways – all but seven – are linked to Alzheimer’s disease. Almost half of the signaling pathways have been linked to Alzheimer’s disease in more than 100 scientific papers.

Researchers at Beth Israel Deaconess Medical Center (BIDMC) recently conducted a study to understand the breadth and diversity of biological signaling pathways  important molecular chain reactions that trigger cellular changes that have contributed to Alzheimer’s disease through research over the past 30 years. To do this, they carried out a systematic evaluation of more than 200,000 scientific publications.

The team discovered that despite significant technological advances, the most commonly associated biological mechanisms, such as those related to the immune system, metabolism and long-term depression, have not changed significantly over the past 30 years, even though almost all known signaling pathways have changed have been associated with the disease. The researchers’ work, published in Frontiers in Aging Neuroscience, will further study the causes of neurodegeneration.

“The burden of Alzheimer’s disease continues to mount, pushing us toward a neurological epidemic,” said Winston A. Hide, PhD, director of the Core Facility for Precision RNA Medicine at BIDMC and associate professor of medicine at Harvard Medical School.

“Our findings suggest that not only is this disorder incredibly complex, but that its pathology encompasses most of the known biological pathways. This means that the effects of the disease on the body are much more extensive than we thought.”

The team performed a comprehensive text search of 206,324 publications on pathway-specific dementia published since 1990. Next, they examined 341 known biological pathways and determined how many publications linked a particular pathway to the disease.

The researchers found that 91% of the signaling pathways – all but seven – are linked to Alzheimer’s disease. Almost half of the signaling pathways have been linked to Alzheimer’s disease in more than 100 scientific papers.

They also found that the 30 signaling pathways most commonly cited in the literature have remained relatively constant over the past 30 years, suggesting that most studies of the disease have focused on a small subset of all known disease-associated signaling pathways.

“Clinical trials aimed at either delaying the onset or slowing the progression of Alzheimer’s disease have largely failed,” said study lead author Sarah Morgan, who was a postdoctoral fellow at BIDMC during the scope of this research and now an associate professor at the Queen Mary University of London.

“Given the unexpected diversity of signaling pathways associated with Alzheimer’s disease, a variety of disease processes are not successfully addressed in clinical trials. We anticipate that a broad focus on more of the associated underlying mechanisms of Alzheimer’s disease will increase the chances of success in future drug trials.”

Leave a Comment